Wegovy Results: What Weight Loss Can You Actually Expect?

If you want a single number, here it is: in the STEP-1 trial, adults taking Wegovy (semaglutide) at the full 2.4mg weekly dose lost, on average, 14.9% of their body weight over 68 weeks, compared with 2.4% for those on placebo plus lifestyle support. For someone starting at 100kg, that average works out at roughly 15kg — about two and a half stone.

But an average is a poor guide to your own outcome. Some people in that trial lost a third of their body weight; others lost very little. The honest answer to "what results will I get on Wegovy?" is that the medicine gives most people a genuine, measurable advantage over willpower alone — and the size of that advantage depends on your starting point, the dose you reach, how you eat and move alongside it, and your individual biology.

This guide walks through what the evidence actually shows, how the results build over time, why they differ so much between people, and what to do when the scales stop moving. Wegovy is a prescription-only medicine in the UK, and it is only ever supplied after an online consultation and clinical assessment by a prescriber — so we'll also be clear about who it's licensed for and where the safety limits lie.

What "average" Wegovy results really mean

Semaglutide is a GLP-1 receptor agonist. It mimics a gut hormone your body releases after eating, which does two useful things: it dampens appetite and the constant background "food noise" that pulls you toward snacking, and it slows how quickly your stomach empties, so you feel full sooner and for longer. It is not a fat-burner and it does nothing to fat tissue directly — it changes how much you want to eat.

The headline efficacy figure comes from STEP-1, the pivotal 68-week randomised trial published in the New England Journal of Medicine in 2021. Adults with obesity (or overweight with a weight-related condition), without diabetes, taking 2.4mg weekly alongside lifestyle intervention lost a mean of 14.9% of body weight. Around a third of participants lost 20% or more. Results vary — that spread between people is the point, not a footnote.

It helps to translate the percentage into something concrete:

The benefits also reach beyond the scale. In the SELECT trial, semaglutide 2.4mg reduced the risk of major cardiovascular events — heart attack, stroke, or cardiovascular death — by 20% in adults with established cardiovascular disease and overweight or obesity, but without diabetes. Weight loss of this scale also tends to improve blood pressure, blood-sugar control, and the load on weight-bearing joints. That cardiovascular result comes from a specific secondary-prevention group, so it shouldn't be read as a benefit every patient can expect — none of it is guaranteed for any one person, but it's the direction the evidence points.

The Wegovy weight-loss timeline

Wegovy is a slow build, by design. You don't start on the effective dose — you climb to it over about four months through a fixed titration schedule, giving your gut time to adjust and keeping side effects manageable. The standard UK escalation is:

Months one and two are about tolerance, not transformation. The 0.25mg and 0.5mg doses are deliberately below the level that drives meaningful fat loss — their job is to let your body settle. You may see the scales move a little, but early changes are often water and reduced bloating rather than fat. Don't be tempted to jump doses to speed things up; that mostly buys you nausea, not faster results.

Month three onwards is usually where fat loss accelerates. By the 1.0mg and 1.7mg doses the appetite effect becomes more consistent and the food noise fades noticeably for most people. Once you reach 2.4mg, the emphasis shifts from losing weight to holding the loss and consolidating the metabolic gains.

There is a built-in checkpoint worth knowing about. Guidance recommends a clinical review once you have spent time on the full maintenance dose: if you haven't lost at least 5% of your starting weight by that point, semaglutide may not be the right treatment for you, and continuing isn't automatically the answer. It's a safety mechanism, not a verdict on your effort.

Why results vary so much between people

The 14.9% average hides a wide spread, and several things explain where you land within it.

You may be a lower responder. In trials, a minority of people saw only modest weight change despite following the schedule faithfully. This is not a willpower failure — it reflects differences in how individual bodies respond to GLP-1 signalling. If the appetite effect simply doesn't land strongly for you, that becomes clear within the first few months, which is exactly what the maintenance-dose review is there to catch.

Your starting BMI shapes the trajectory. People starting at a higher weight often see larger absolute drops early on. The goal, though, is fat loss while protecting lean muscle — which is why protein intake matters throughout (more on that below).

Biology and life stage play a part. Hormonal changes around the menopause can slow the rate of loss for some women, and men often see a faster early drop partly because more muscle mass keeps their resting metabolism higher. Your body also defends a "set point" weight, and semaglutide works partly by lowering the signals that guard it — but genetics can make that shift more stubborn for some than others.

How you eat and move alongside it is decisive. The medicine creates the appetite reduction; what you do with it determines the quality of the result. Adequate protein, some resistance or strength movement, and steady daily activity all help preserve muscle and keep the loss going.

Wegovy versus Mounjaro results

The obvious comparison is Mounjaro (tirzepatide), which acts on two gut hormones — GLP-1 and GIP — rather than one. In its own pivotal trial, SURMOUNT-1, tirzepatide at the top 15mg dose produced a mean weight loss of around 22.5% over 72 weeks. That is a different trial with a different design, so the numbers aren't a like-for-like race, but the dual-hormone approach does tend to produce larger average losses.

That does not make Wegovy the "loser." Semaglutide has a long real-world track record, robust cardiovascular outcome data, and suits many people well. The right choice is about your metabolic profile, tolerance, and what a prescriber judges appropriate — not simply picking the biggest headline number. You can read a fuller side-by-side on our Mounjaro and Wegovy pages, and there's now an oral option worth knowing about on the Wegovy Tablet page too.

Managing plateaus and side effects

Weight loss on Wegovy is rarely a straight line. It's more often a series of drops followed by flat stretches, and expecting the scale to fall every single week sets you up for needless disappointment.

Why plateaus happen. As you lose weight there is simply less of you to fuel, so your resting energy use falls — a normal process called metabolic adaptation. Your body also becomes more efficient and, over time, small amounts of "calorie creep" can quietly return as the initial appetite suppression settles. This is why protein matters: it protects muscle, which is the tissue that keeps your metabolism ticking over, and it has a higher thermic effect than fat or carbohydrate. When the scale stalls for two or three weeks, that's usually recalibration, not failure. Look for non-scale signs too — waist measurement, how clothes fit, energy levels. If you're genuinely stuck for more than four weeks, it's worth reviewing intake, hydration, and daily movement with your prescriber.

Side effects, honestly. Most side effects are gastrointestinal and cluster in the early weeks and after each dose increase:

• Nausea — the most common, often strongest in the 24–48 hours after an injection and easing as you adjust
• Constipation — from reduced food volume and slower gut transit
• Fatigue — partly the calorie deficit, partly the metabolic shift
• Burping, reflux, or an early feeling of fullness — a knock-on of slower stomach emptying

Practical management helps: eat smaller portions, don't wait until you feel starving, hydrate well, add fibre for constipation, and go easy on heavy, high-fat meals around injection day.

Some risks are rare but serious and worth naming. Semaglutide can cause gallbladder problems (including gallstones) and, uncommonly, pancreatitis. Severe, persistent abdominal pain — especially pain that bores through to your back, with or without vomiting — needs urgent medical attention. Suspected side effects can be reported to the MHRA through the Yellow Card scheme at yellowcard.mhra.gov.uk, which helps monitor the safety of medicines in the UK.

On the question of who shouldn't take it: Wegovy is contraindicated in anyone with a known hypersensitivity to semaglutide or the other ingredients in the pen, and in people with a personal or family history of medullary thyroid carcinoma or the MEN 2 syndrome. It also isn't recommended in pregnancy or while breastfeeding, and it calls for caution in people with severe gastrointestinal disease, such as significant gastroparesis. This is not the full list — your prescriber assesses your individual history against it before prescribing.

Who Wegovy is licensed for

Wegovy holds a UK marketing authorisation from the Medicines and Healthcare products Regulatory Agency (MHRA) as an addition to a reduced-calorie diet and increased physical activity for adults with:

• a BMI of 30 or more (obesity), or
• a BMI of 27 or more (overweight) with at least one weight-related condition such as high blood pressure, type 2 diabetes, high cholesterol, or obstructive sleep apnoea.

These licensed thresholds are broader than the stricter criteria the NHS uses to decide who it will fund through specialist weight-management services, which is why many people who qualify clinically choose a regulated private route. Either way, semaglutide is prescription-only: it can never legitimately be bought without a prescription, and a genuine provider will always assess your suitability first.

How it works at The Weight Clinic

The Weight Clinic is a GPhC-registered UK online pharmacy, and every prescription is the outcome of a real clinical process — not a checkout button. You complete a confidential online consultation covering your weight and height, medical history, and current medicines; a prescriber reviews it against the licensing criteria and safety checks above; and treatment is only supplied if it's appropriate for you. If it isn't, we'll say so.

Wegovy at The Weight Clinic starts from £80 for your first month (£115 standard, with £35 off your first order using code NEWME), with no subscription lock-in. Semaglutide is temperature-sensitive, so it's sent in cold-chain packaging to arrive ready to use. Because we're a pharmacy rather than an app, you have qualified people to turn to when side effects hit or the scales stall.

If you're weighing it up, the first step costs nothing: check your eligibility with a short online assessment and a prescriber will tell you honestly whether Wegovy — or another option — fits.

The bottom line

Wegovy gives most people a real, evidence-backed head start: an average of 14.9% body-weight loss over 68 weeks in STEP-1, built slowly through titration to the 2.4mg dose, with cardiovascular benefits shown in SELECT on top for a specific higher-risk group. Your own figure will sit somewhere on a wide range, shaped by your starting point, your dose, how you eat and move, and your biology — and roughly one in ten people respond only modestly, which the maintenance-dose review is designed to catch. Treated as a medicine with clinical support rather than a quick fix, it's a well-founded tool for managing weight as the long-term condition it is.

If you'd like to explore your options further, our guides to Mounjaro, the Wegovy Tablet, and weight-loss injections go deeper on the alternatives.